# US 2023/0145991 A1 · T cell compositions for immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0145991 A1
- Document ID: US20230145991A1
- Status: Published application
- Kind: A1
- Application number: 17/807,213
- Filed: 2022-06-16
- Published: 2023-05-11
- Earliest claimed: 2016-06-28
- Assignees: Geneius Biotechnology, Inc.
- Applicants: Geneius Biotechnology, Inc.
- Inventors: Alfred E. SLANETZ; Terry Y. NAKAGAWA; Marissa A. HERRMAN
- Web page: https://patentgrep.com/patent/US20230145991A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4201: {Neoantigens}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.

## Claims

### Claim 1

A method for making a composition comprising T cells, the method comprising the steps of:
(a) obtaining an initial cell population comprising T-cells;
(b) stimulating the T-cells by exposing the initial cell population to one or more target antigens and to cytokines resulting in a first intermediate cell population,
(c) culturing the first intermediate cell population in media comprising cytokines resulting in a second intermediate cell population;
(d) exposing the second intermediate cell population to tetrameric antibodies that bind CD3, CD28, and CD2 to effect polyclonal stimulation of the T-cells in the second intermediate cell population resulting in a third intermediate cell population;
(e) testing the third intermediate cell population for antigen-specific reactivity; and
(f) harvesting the resulting composition comprising T-cells to obtain a final T-cell population.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the cytokines in steps (b) and (c) individually comprise one or more of IL-2, IL-7, IL-15, and IL-21.

### Claim at position 4

-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the initial cell population is divided into two or more sub-populations, which are each stimulated by exposure to different target antigens.

### Claim at position 6

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the one or more target antigens comprises a plurality of overlapping peptides derived from the one or more target antigens, and wherein the one or more target antigens comprise polypeptides derived from one or more sub-dominant antigens or polypeptides derived from one or more neoantigens.

### Claim at position 8

-14. (canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the one or more target antigens comprises polypeptides derived from viral antigens, wherein the viral antigens are derived from one or more of cytomegalovirus, Epstein-Barr virus, hepatitis B virus, human papillomavirus, adenovirus, herpes virus, human immunodeficiency virus, influenza virus, human respiratory syncytial virus, vaccinia virus, Varicella-zoster virus, Yellow fever virus, Ebola virus, and Zika virus.

### Claim at position 10

-18. (canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the final T-cell population comprises greater than 70% CD3+ T-cells with predominantly CD8+ versus CD4+ T-cells.

### Claim 20 (depends on 1)

The method of claim 1, wherein the final T-cell population comprises greater than about 1% of the total CD3+ cells having reactivity toward the antigen or antigens.

### Claim 21 (depends on 1)

The method of claim 1, wherein the T-cell composition resulting from the method comprises T-cells having elevated surface expression of CD62L, CCR7 or CXCR3 and decreased surface expression of one or more activation/exhaustion markers LAG3, CD244(2B4), CD160, TIM-3, CTLA-4.

### Claim 22

A method for making a composition comprising T cells, the method comprising the steps of:
(a) obtaining an initial cell population comprising T-cells;
(b) selecting T-cells based on expression of T-cell activation markers resulting in a selected cell population,
(c) exposing the selected cell population to tetrameric antibodies that bind CD3, CD28, and CD2 to effect polyclonal stimulation of the T-cells in the selected cell population resulting in an intermediate cell population;
(d) polyclonal stimulation of the T-cells in the intermediate cell population, and
(e) harvesting the resulting composition-comprising a final cell population of T-cells.

### Claim 23 (depends on 22)

The method of claim 22, wherein the method further comprises stimulating the T-cells by exposing the initial cell population to one or more target antigens and to cytokines prior to step (b).

### Claim 24

(canceled)

### Claim 25 (depends on 22)

The method of claim 22, wherein step (b) is performed about 7 days after stimulating the T-cells by exposing the initial cell population to one or more target antigens and to cytokines.

### Claim 26 (depends on 23)

The method of claim 23, wherein the cytokines comprise one or more of IL-2, IL-7, IL-15, and IL-21.

### Claim 27

(canceled)

### Claim 28 (depends on 22)

The method of claim 22, wherein the T-cell activation markers in step (b) comprises one or more of CD69, CD279(PD-1), CD223(LAG3), CD134(OX40), CD183(CXCR3), CD27(IL-7Ra), CD137(4-1BB), CD366(TIM3), CD25(IL-2Ra), CD80, CD152(CTLA-4), CD28, CD278(IOS), CD154(CD40L), and CD45RO).

### Claim 29

(canceled)

### Claim 30 (depends on 23)

The method of claim 23, wherein the one or more target antigens comprises a plurality of overlapping peptides derived from the one or more target antigens, and wherein the one or more target antigens comprise polypeptides derived from one or more sub-dominant antigens.

### Claim at position 23

-32. (canceled)

### Claim 33 (depends on 30)

The method of claim 30, wherein the one or more target antigens comprises polypeptides derived from viral antigens, wherein the viral antigens are derived from one or more of cytomegalovirus, Epstein-Barr virus, hepatitis B virus, human papillomavirus, adenovirus, herpes virus, human immunodeficiency virus, influenza virus, human respiratory syncytial virus, vaccinia virus, Varicella-zoster virus, Yellow fever virus, Ebola virus, and Zika virus.

### Claim at position 25

-37. (canceled)

### Claim 38 (depends on 1)

A method for treating a subject in need of immunotherapy comprising administering to the subject a composition comprising T-cells, wherein the composition is made by the method of claim 1.

### Claim 39 (depends on 22)

A method for treating non-Hodgkin's lymphoma, gastric cancer, or nasopharyngeal carcinoma by administering to a patient in need thereof a T-cell composition enriched for T-cells reactive to one or more EBV antigens, wherein the T cell composition is made by the method of claim 22.

### Claim 40 (depends on 22)

A method for treating glioblastoma by administering to a patient in need thereof a T-cell composition enriched for T-cells reactive to one or more of pp65, Cancer/testis antigen 1 (NY-ESO-1), and Survivin, wherein the T cell composition is made by the method of claim 22.

### Claim 41

A composition comprising T-cells for immunotherapy wherein the composition comprises greater than half a million CD3+ cells, wherein the live cells comprise greater than 70% CD3+ T-cells, and wherein the T-cells are predominantly CD8+ versus CD4+ T-cells and are predominantly effector memory T-cells.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the T-cells in the composition display minimal exhaustion markers, high expression levels of lymphocyte homing and trafficking markers, and high antigen reactivity.
